142 related articles for article (PubMed ID: 37979399)
1. Cancer incidence in Familial Mediterranean Fever: A retrospective analysis.
Baspinar SN; Kilic B; Azman FN; Guler Y; Gunay UB; Tanin MK; Can G; Ugurlu S
Semin Arthritis Rheum; 2023 Dec; 63():152284. PubMed ID: 37979399
[TBL] [Abstract][Full Text] [Related]
2. Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia.
Bilgin E; Dizdar Ö; Güven DC; Ceylan S; Aybi Ö; Fırlatan B; Kardaş RC; Yıldırım T; Hayran MK; Kalyoncu U; Özen S
Rheumatol Int; 2019 Jun; 39(6):1045-1051. PubMed ID: 31025139
[TBL] [Abstract][Full Text] [Related]
3. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
Koga T; Sato S; Miyamoto J; Hagimori N; Kawazoe Y; Arinaga K; Fukushima C; Yamamoto H; Kawakami A
Trials; 2018 Dec; 19(1):715. PubMed ID: 30594222
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in adult patients with Familial Mediterranean fever living in Germany or Turkey compared to healthy subjects: a study evaluating the effect of disease severity and country of residence.
Giese A; Kurucay M; Kilic L; Örnek A; Şendur SN; Lainka E; Henning BF
Rheumatol Int; 2013 Jul; 33(7):1713-9. PubMed ID: 23274441
[TBL] [Abstract][Full Text] [Related]
6. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.
Hentgen V; Vinit C; Fayand A; Georgin-Lavialle S
Front Immunol; 2020; 11():971. PubMed ID: 32670263
[No Abstract] [Full Text] [Related]
7. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever.
Alpay N; Sumnu A; Calışkan Y; Yazıcı H; Türkmen A; Gül A
Rheumatol Int; 2012 Oct; 32(10):3277-9. PubMed ID: 20386914
[TBL] [Abstract][Full Text] [Related]
8. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
Özçakar ZB; Özdel S; Yılmaz S; Kurt-Şükür ED; Ekim M; Yalçınkaya F
Clin Rheumatol; 2016 Feb; 35(2):441-6. PubMed ID: 25213327
[TBL] [Abstract][Full Text] [Related]
9. Gray zone in the spectrum of autoinflammatory diseases: familial Mediterranean fever accompanying periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome: single-center experience.
Konte EK; Haslak F; Yildiz M; Gucuyener N; Ulkersoy I; Gunalp A; Aslan E; Adrovic A; Sahin S; Barut K; Kasapcopur O
Eur J Pediatr; 2023 Dec; 182(12):5473-5482. PubMed ID: 37777601
[TBL] [Abstract][Full Text] [Related]
10. Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).
El Hasbani G; Jawad A; Uthman I
Orphanet J Rare Dis; 2019 Oct; 14(1):224. PubMed ID: 31615541
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF.
Erten S; Erten SF; Altunoglu A
Rheumatol Int; 2012 Apr; 32(4):1095-7. PubMed ID: 21431291
[TBL] [Abstract][Full Text] [Related]
12. Familial Mediterranean Fever and Incidence of Cancer: An Analysis of 8,534 Israeli Patients With 258,803 Person-Years.
Brenner R; Ben-Zvi I; Shinar Y; Liphshitz I; Silverman B; Peled N; Levy C; Ben-Chetrit E; Livneh A; Kivity S
Arthritis Rheumatol; 2018 Jan; 70(1):127-133. PubMed ID: 28992365
[TBL] [Abstract][Full Text] [Related]
13. Familial Mediterranean fever-associated infertility and underlying factors.
Atas N; Armagan B; Bodakci E; Satis H; Sari A; Bilge NSY; Salman RB; Yardımcı GK; Babaoglu H; Kilic L; Ozturk MA; Goker B; Haznedaroglu S; Kasifoglu T; Kalyoncu U; Tufan A
Clin Rheumatol; 2020 Jan; 39(1):255-261. PubMed ID: 31502094
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360
[TBL] [Abstract][Full Text] [Related]
15. Biologic therapy in familial Mediterranean fever.
Koga T; Migita K; Kawakami A
Mod Rheumatol; 2016 Sep; 26(5):637-41. PubMed ID: 26939747
[TBL] [Abstract][Full Text] [Related]
16. Non-response to colchicine in familial Mediterranean fever should be identified accurately.
Melikoglu MA; Senel K
Int J Rheum Dis; 2017 Dec; 20(12):2118-2121. PubMed ID: 24702830
[TBL] [Abstract][Full Text] [Related]
17. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
[TBL] [Abstract][Full Text] [Related]
18. Familial Mediterranean fever in childhood: a single-center experience.
Barut K; Sahin S; Adrovic A; Sinoplu AB; Yucel G; Pamuk G; Aydın AK; Dasdemir S; Turanlı ET; Buyru N; Kasapcopur O
Rheumatol Int; 2018 Jan; 38(1):67-74. PubMed ID: 28828621
[TBL] [Abstract][Full Text] [Related]
19. Normal arterial stiffness in familial Mediterranean fever. Evidence for a possible cardiovascular protective role of colchicine.
Kukuy O; Livneh A; Mendel L; Benor A; Giat E; Perski O; Feld O; Kassel Y; Ben-Zvi I; Lidar M; Holtzman EJ; Leiba A
Clin Exp Rheumatol; 2017; 35 Suppl 108(6):32-37. PubMed ID: 28229824
[TBL] [Abstract][Full Text] [Related]
20. [Familial Mediterranean fever: not to be missed].
Frenkel J; Bemelman FJ; Potter van Loon BJ; Simon A
Ned Tijdschr Geneeskd; 2013; 157(18):A5784. PubMed ID: 23635502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
